GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Shares Outstanding (EOP)

Stayble Therapeutics AB (STU:4K4) Shares Outstanding (EOP) : 31.72 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Stayble Therapeutics AB's shares outstanding for the quarter that ended in Sep. 2023 was 31.72 Mil.

Stayble Therapeutics AB's quarterly shares outstanding stayed the same from Jun. 2023 (31.72 Mil) to Sep. 2023 (31.72 Mil).

Stayble Therapeutics AB's annual shares outstanding stayed the same from Dec. 2021 (14.23 Mil) to Dec. 2022 (14.23 Mil).


Stayble Therapeutics AB Shares Outstanding (EOP) Historical Data

The historical data trend for Stayble Therapeutics AB's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Shares Outstanding (EOP) Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial 8.92 8.92 8.93 14.23 14.23

Stayble Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.23 14.23 13.85 31.72 31.72

Competitive Comparison of Stayble Therapeutics AB's Shares Outstanding (EOP)

For the Biotechnology subindustry, Stayble Therapeutics AB's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stayble Therapeutics AB's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Shares Outstanding (EOP) falls into.



Stayble Therapeutics AB Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Stayble Therapeutics AB  (STU:4K4) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Stayble Therapeutics AB Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Stayble Therapeutics AB (STU:4K4) Business Description

Traded in Other Exchanges
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines